{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:54:35Z","timestamp":1790985275081,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Japanese Hospice Palliative Care Foundation and JSPS KAKENHI","award":["JP20K16567"],"award-info":[{"award-number":["JP20K16567"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00520-022-07057-8","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:04:46Z","timestamp":1650575086000},"page":"6233-6241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score\u2013weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process"],"prefix":"10.1007","volume":"30","author":[{"given":"Ken","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-2161","authenticated-orcid":false,"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naosuke","family":"Yokomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Takatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"7057_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589\u2013597","journal-title":"Eur J Cancer"},{"key":"7057_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM199402033300508","volume":"330","author":"BA Runyon","year":"1994","unstructured":"Runyon BA (1994) Care of patients with ascites. N Engl J Med 330:337\u2013342","journal-title":"N Engl J Med"},{"key":"7057_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/00004836-199403000-00002","volume":"18","author":"BA Runyon","year":"1994","unstructured":"Runyon BA (1994) Malignancy-related ascites and ascitic fluid \u201chumoral tests of malignancy.\u201d J Clin Gastroenterol 18:94\u201398","journal-title":"J Clin Gastroenterol"},{"key":"7057_CR4","first-page":"15","volume":"82","author":"S Wilailak","year":"1999","unstructured":"Wilailak S, Linasmita V, Srivannaboon S (1999) Malignant ascites in female patients: a seven-year review. J Med Assoc Thai 82:15\u201319","journal-title":"J Med Assoc Thai"},{"key":"7057_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jso.2930200411","volume":"20","author":"P Appelqvist","year":"1982","unstructured":"Appelqvist P, Silvo J, Salmela L et al (1982) On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20:238\u2013242","journal-title":"J Surg Oncol"},{"key":"7057_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/1097-0142(19890801)64:3<753::AID-CNCR2820640330>3.0.CO;2-Y","volume":"64","author":"QS Ringenberg","year":"1989","unstructured":"Ringenberg QS, Doll DC, Loy TS et al (1989) Malignant ascites of unknown origin. Cancer 64:753\u2013755","journal-title":"Cancer"},{"key":"7057_CR7","first-page":"474","volume":"6","author":"JR Mackey","year":"1996","unstructured":"Mackey JR, Venner PM (1996) Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 6:474\u2013480","journal-title":"Can J Oncol"},{"key":"7057_CR8","first-page":"644","volume":"203","author":"RN Garrison","year":"1986","unstructured":"Garrison RN, Kaelin LD, Galloway RH et al (1986) Malignant ascites. Clinical and experimental observations Ann Surg 203:644\u2013651","journal-title":"Clinical and experimental observations Ann Surg"},{"key":"7057_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","volume":"16","author":"CW Lee","year":"1998","unstructured":"Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manag 16:96\u2013101","journal-title":"J Pain Symptom Manag"},{"key":"7057_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11864-008-0068-y","volume":"9","author":"M Chung","year":"2008","unstructured":"Chung M, Kozuch P (2008) Treatment of malignant ascites. Curr Treat Options Oncol 9:215\u2013233","journal-title":"Curr Treat Options Oncol"},{"key":"7057_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty SL, Miner TJ (2012) Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87\u201395","journal-title":"World J Gastrointest Surg"},{"key":"7057_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","volume":"120","author":"C Hodge","year":"2019","unstructured":"Hodge C, Badgwell BD (2019) Palliation of malignant ascites. J Surg Oncol 120:67\u201373","journal-title":"J Surg Oncol"},{"key":"7057_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/0256-4947.55167","volume":"29","author":"MW Saif","year":"2009","unstructured":"Saif MW, Siddiqui IA, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29:369\u2013377","journal-title":"Ann Saudi Med"},{"key":"7057_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945\u2013949","journal-title":"Ann Oncol"},{"key":"7057_CR15","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00520-014-2557-9","volume":"23","author":"CF Jehn","year":"2015","unstructured":"Jehn CF, K\u00fcpferling S, Oskay-\u00d6zcelik G et al (2015) A survey of treatment approaches of malignant ascites in Germany and Austria. Support Care Cancer 23:2073\u20132078","journal-title":"Support Care Cancer"},{"key":"7057_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1089\/jpm.2018.0595","volume":"22","author":"T Hisanaga","year":"2019","unstructured":"Hisanaga T, Shinjo T, Imai K et al (2019) Clinical guidelines for management of gastrointestinal symptoms in cancer patients: the Japanese Society of Palliative Medicine recommendations. J Palliat Med 22:986\u2013997","journal-title":"J Palliat Med"},{"key":"7057_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(15)00401-5","volume":"17","author":"I Maeda","year":"2016","unstructured":"Maeda I, Morita T, Yamaguchi T et al (2016) Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol 17:115\u2013122","journal-title":"Lancet Oncol"},{"key":"7057_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(09)70032-4","volume":"10","author":"LJ Materstvedt","year":"2009","unstructured":"Materstvedt LJ, Bosshard G (2009) Deep and continuous palliative sedation (terminal sedation): clinical-ethical and philosophical aspects. Lancet Oncol 10:622\u2013627","journal-title":"Lancet Oncol"},{"key":"7057_CR19","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00520-014-2200-9","volume":"22","author":"EE Papavasiliou","year":"2014","unstructured":"Papavasiliou EE, Payne S, Brearley S et al (2014) Current debates on end-of-life sedation: an international expert elicitation study. Support Care Cancer 22:2141\u20132149","journal-title":"Support Care Cancer"},{"key":"7057_CR20","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1007\/s00520-020-05408-x","volume":"28","author":"Y Hiratsuka","year":"2020","unstructured":"Hiratsuka Y, Yamaguchi T, Maeda I et al (2020) The Functional Palliative Prognostic Index: a scoring system for functional prognostication of patients with advanced cancer. Support Care Cancer 28:6067\u20136074","journal-title":"Support Care Cancer"},{"key":"7057_CR21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, Gilet H, Gonschior AK et al (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 23:1979\u20131985","journal-title":"Ann Oncol"},{"key":"7057_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","volume":"10","author":"S Greenland","year":"1999","unstructured":"Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. Epidemiology 10:37\u201348","journal-title":"Epidemiology"},{"key":"7057_CR23","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661\u20133679","journal-title":"Stat Med"},{"key":"7057_CR24","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657","journal-title":"BMJ"},{"key":"7057_CR25","unstructured":"Hern\u00e1n MA RJ (2020) Causal inference: what if. CRC: Boca Raton: Chapman & Hall"},{"key":"7057_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: issues and guidance for practice. Stat Med 30:377\u2013399","journal-title":"Stat Med"},{"key":"7057_CR27","unstructured":"Rubin DB (2004) Multiple imputation for nonresponse in surveys. John Wiley & Sons"},{"key":"7057_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jpainsymman.2021.04.010","volume":"62","author":"T Ito","year":"2021","unstructured":"Ito T, Yokomichi N, Ishiki H et al (2021) Optimal paracentesis volume for terminally ill cancer patients with ascites. J Pain Symptom Manage 62:968\u2013977","journal-title":"J Pain Symptom Manage"},{"key":"7057_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269216313486952","volume":"27","author":"NJ Preston","year":"2013","unstructured":"Preston NJ, Fayers P, Walters SJ et al (2013) Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: part of the MORECare research method guidance on statistical issues. Palliat Med 27:899\u2013907","journal-title":"Palliat Med"},{"key":"7057_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/cncr.27854","volume":"119","author":"D Hui","year":"2013","unstructured":"Hui D, Glitza I, Chisholm G et al (2013) Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer 119:1098\u20131105","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07057-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:33:34Z","timestamp":1653557614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07057-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["7057"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07057-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The EASED study was performed in accordance with the ethical standards of the Helsinki declaration and the ethical guidelines for epidemiological research presented by the Ministry of Health, Labour and Welfare in Japan. The study protocol was reviewed and approved by the local institutional review boards of all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Japanese law does not require individual informed consent from participants in a non-invasive observational trial. Therefore, we used an opt-out method rather than acquiring written or oral informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Ishiki reports personal fees from Mundipharma, Morinaga Clinico, Merck Serono, and Guerbet Japan and non-financial support from Shionogi outside of the submitted work; Dr. Masuda reports personal fees from Chugai and AstraZeneca outside of the submitted work. All other authors state that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}